clinical_trials
STAT+: GSK sees its return to cancer starting to pay off
Confidence88·multiple reportsImportance90NP-EVT-20261026-34F6E98
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
Read the original at the primary source
STAT+: GSK sees its return to cancer starting to pay off
Andrew Joseph · 10/26/2026, 4:20:05 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —